Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMULAB – Pembrolizumab plus local ablation in early-stage hepatocellular carcinoma
2018-001381-42Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Oct 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in hepatocellular carcinoma (HCC), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Objective response rate. Started Oct 2018; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2018-001381-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001381-42.